Erratum: Tadalafil is efficacious in Black American and Hispanic men with erectile dysfunction: Results from multiple observations in men with erectile dysfunction in National Tadalafil Study in the US (MOMENTUS) (International Journal of Impotence Research (2007) 19, (76-83) DOI: 10.1038/sj.ijir.3901484);Tadalafil is efficacious in Black American and Hispanic men with erectile dysfunction: Results from multiple observations in men with erectile dysfunction in national tadalafil study in the US (MOMENTUS)

International Journal of Impotence Research

Volumn 19, Issue 1, 2007, Pages 76-83

  Gomery, P ^a   Bullock, A ^a   McGettigan, J ^a   Munarriz, R ^a   Natanegara, F ^a   Hague, J ^a   Kuepfer, C ^a   Abuja, S ^a   Wong, D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Erectile dysfunction; Erectile function; Ethnicity; MOMENTUS; Noninferiority trial; Tadalafil

Indexed keywords

TADALAFIL;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BACKACHE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; ETHNIC DIFFERENCE; HISPANIC; HOT FLUSH; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; OPTIMAL DRUG DOSE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; RHINOPHARYNGITIS; SCORING SYSTEM; SEXUAL INTERCOURSE; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 33846041791     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901535     Document Type: Erratum

References (23)

1. National Institutes of Health Consensus Development Panel on Impotence. Impotence. JAMA 1993; 270: 83-90.
2. Feldman HA, Golstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
3. Sowers JR, Ferdinand KC, Bakris GL, Douglas JG. Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcome. Postgrad Med 2002; 112: 24-26, 29-30, 33-34.
4. Gillum RF. Risk factors for stroke in blacks: a critical review. Am J Epidemiol 1999; 150: 1266-1274.
5. Haffner SM, Morales PA, Hazuda HP, Stern MP. Levels of control of hypertension in Mexican-Americans and non-Hispanic whites. Hypertension 1993; 21: 83-88.
6. Mitchell BD, Stern MP, Haffner SM, Hazuda HP, Patterson JK. Risk factors for cardiovascular mortality in Mexican-Americans and non-Hispanic whites. San Antonio heart study. Am J Epidemiol 1990; 131: 423-433.
7. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332.
8. Hellstrom WJG, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763.
9. Goldstein G, Lue TF, Padma-Nathan H, Rosen R, Steers W, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397.
10. Carson CC, Rajfer J, Eardley I, Carrier S, Dennes JS, Walker DJ et al. The efficacy and safety of tadalafil: an update. BJU Int 2004; 93: 1276.
11. Ponholzer A, Temml C, Mock K, Marszalek M, Obermayr R, Madersbacher S. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 2005; 47: 80-86.
12. Shabsigh R, Klein LT, Seidman S, Kaplan SA, Lehrhoff BJ, Ritter JS. Increased incidence of depressive symptoms in men with erectile dysfunction. Urology 1998; 52: 848-852.
13. Kulkarni PM, Meadows ES, Ahuja S, Muram D, Plouffe L. Rationale for a non-inferiority clinical trial design focused on subpopulations. Curr Med Res Opin 2004; 20: 1641-1647.
14. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for the assessment of erectile dysfunction. Urology 1997; 49: 822-830.
15. Mulhall JP. Deciphering erectile dysfunction drug trials. J Urol 2003; 170: 353-358.
16. Rosen RC, Swindle R, Lockhart D, Cameron A. Psychological and Interpersonal Relationship Scales (PAIRS): a new tool to measure psychological and relationship impacts of ED treatments. Presented at: 5th Congress of the European Society for Sexual and Impotence Research. December 1-4, 2002; Hamburg, Germany.
17. Points to consider on switching between superiority and noninferiority. CPMP web site. Available at: http://www.emea.eu.int/pdfs/human/ewp/048299en.pdf. Accessed 18 July 2005.
18. Agostino RB, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics. Stat Med 2003; 22: 169-186.
19. Points to consider on switching between superiority and noninferiority. CPMP web site. Available at: http://www.emea.eu.int/pdfs/human/ewp/215899en.pdf. Accessed 18 July 2005.
20. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313: 36-39.
21. Young JM, Bennet C, Gilhooly P, Wessells H, Ramos DE. Efficacy and safety of sildenafil citrate (Viagra®) in Black and Hispanic American Men. Urology 2002; 60: 39-48.
22. Bennett J, Shapiro J, Taylor T. Vardenafil improves erectile function in African-American, Hispanic, and Caucasian men with erectile dysfunction (ED). Poster presented at SMSNA 2003.
23. Morgentaler A, Barada J, Niederberger C, Garcia CS, Natanegara F, Ahuja S et al. MOMENTUS: multiple observations in men with erectile dysfunction in national tadalafil study in the US [abstract]. ASA 2005 Abstract 33.